BusinessOcera Therapeutics to Report First Quarter 2017 Financial Results and Provide Clinical Update on May 9, 2017By Nasdaq OMXMay 3, 2017, 8:05 PM UTC
BusinessOcera Therapeutics Announces Presentation of Data Showing OCR-002 Prevented Progression of Fibrosis in Preclinical Model of Non-alcoholic Fatty Liver Disease (NAFLD)By Nasdaq OMXApr 12, 2017, 8:08 PM UTC
BusinessOcera Therapeutics Announces Presentation of Data Showing OCR-002 Prevented Progression of Fibrosis in Preclinical Model of Non-alcoholic Fatty Liver Disease (NAFLD)By Nasdaq OMXApr 12, 2017, 8:08 PM UTC
BusinessOcera Therapeutics Announces Presentation of Data Showing OCR-002 Prevented Progression of Fibrosis in Preclinical Model of Non-alcoholic Fatty Liver Disease (NAFLD)By Nasdaq OMXApr 12, 2017, 8:08 PM UTC
BusinessOcera to Present at the 16th Annual Needham Healthcare ConferenceBy Nasdaq OMXMar 27, 2017, 8:05 PM UTC
BusinessOcera to Present at the Stifel 2016 Healthcare ConferenceBy Nasdaq OMXNov 9, 2016, 2:05 PM UTC
BusinessOcera Therapeutics Announces Publication of Promising Preclinical Data in Support of Its Ammonia Scavenger OCR-002 in the Journal of HepatologyBy Nasdaq OMXApr 11, 2016, 1:05 PM UTC
BusinessOcera to Present at the 15th Annual Needham Healthcare ConferenceBy Nasdaq OMXApr 5, 2016, 8:25 PM UTC
